Repligen Corp
NASDAQ:RGEN

Watchlist Manager
Repligen Corp Logo
Repligen Corp
NASDAQ:RGEN
Watchlist
Price: 121.735 USD 3.93% Market Closed
Market Cap: 6.8B USD

Net Margin
Repligen Corp

-2.5%
Current
11%
Average
1.2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-2.5%
=
Net Income
-19.7m
/
Revenue
803.6m

Net Margin Across Competitors

Repligen Corp
Glance View

Repligen Corporation has carved a niche for itself in the dynamic world of bioprocessing, a sector that fuels the global production of biologic drugs. At its core, Repligen specializes in providing innovative technologies and solutions that enhance the efficiency and productivity of manufacturing processes for advanced therapeutics, ranging from monoclonal antibodies to cell and gene therapies. The company operates primarily through its product categories, which include filtration, chromatography, and analytics, bridging the gaps in the biomanufacturing process. By focusing on these critical yet underserved areas, Repligen has positioned itself as a pivotal player enabling pharmaceutical and biotech firms to streamline their production lines, reduce costs, and meet the increasing demand for life-saving biologics. What sets Repligen apart is its strategic approach to generating revenue by staying ahead of industry trends and continuously innovating its product offerings. As biopharmaceutical production shifts towards more personalized and complex therapies, Repligen adeptly supplies the tools and systems required to tackle these challenging demands. The company's revenue model revolves around the sale of its proprietary products, which are essential components in biopharmaceutical manufacturing. By forging strong relationships with industry leaders and consistently delivering high-quality, reliable solutions, Repligen ensures a steady stream of business, leveraging its technological prowess to capture and sustain market share. Through this combination of strategic foresight and steadfast execution, Repligen continues to bolster its reputation as an indispensable ally to the world's leading biotech firms.

RGEN Intrinsic Value
72.093 USD
Overvaluation 41%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-2.5%
=
Net Income
-19.7m
/
Revenue
803.6m
What is the Net Margin of Repligen Corp?

Based on Repligen Corp's most recent financial statements, the company has Net Margin of -2.5%.

Back to Top